ATLANTA, GA – – (February 14, 2018) – – Holzer & Holzer, LLC is investigating whether Tetraphase Pharmaceuticals, Inc. (“Tetraphase” or the “Company”) (NASDAQ: TTPH) complied with the federal securities laws. On February 13, 2018, Tetraphase announced that its IGNITE3 clinical trial did not achieve its co-primary endpoints of responder rate at the end of treatment and test-of-cure visit. The price of Tetraphase stock fell significantly following the announcement. If you purchased Tetraphase common stock and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer Esq. at email@example.com or Alexandria P. Rankin, Esq. at firstname.lastname@example.org, or call the firm by toll-free telephone at (888) 508-6832.